Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd (KPL) last reported results for the quarter ended Jun 2026, with sales of ₹162 crore and net profit of ₹26 crore. The stock last traded at ₹3,679, a market capitalisation of ₹3,817 crore, on a P/E of 46.7. Over the past 52 weeks the stock has ranged between ₹829 and ₹3,949. Figures are as of 6 Oct 2026 and are not real time.
Kwality Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹3,679
- Market cap
- ₹3,817 cr
- Stock P/E
- 46.7
- Book value
- ₹320
- ROE
- 22.6%
- ROCE
- 24.1%
- Dividend yield
- 0.00%
- 52w high / low
- 3949/829
Metrics as of 6 Oct 2026. Not real time.
Track Kwality Pharmaceuticals Ltd
Cruxal reads every Kwality Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Kwality Pharmaceuticals Ltd growth and returns
- 10 Years
- 21%
- 5 Years
- 14%
- 3 Years
- 26%
- TTM
- 38%
- 10 Years
- 44%
- 5 Years
- 35%
- 3 Years
- 29%
- TTM
- 88%
- 10 Years
- 66%
- 5 Years
- 32%
- 3 Years
- 123%
- 1 Year
- 294%
- 10 Years
- 26%
- 5 Years
- 27%
- 3 Years
- 18%
- Last Year
- 23%
Kwality Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹162 cr, up 45.9% from ₹111 cr a year earlier. Net profit was ₹26 cr, up 116.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating profit | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% |
| Other income | 0 | 1 | 1 | 0 | 1 | -0 | 1 | 1 |
| Interest | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% |
| Net profit | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS (₹) | 8.16 | 8.22 | 13.96 | 11.50 | 13.61 | 15.43 | 24.38 | 24.69 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kwality Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 307 | 370 | 503 | 554 |
| Operating profit | 9 | 12 | 16 | 14 | 29 | 172 | 61 | 66 | 80 | 118 | 135 |
| OPM % | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 24% | 24% |
| Net profit | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS (₹) | 3.23 | 4.39 | 7.28 | 8.02 | 14.60 | 115.64 | 18.67 | 22.94 | 38.41 | 64.91 | 78.11 |
TTM is the trailing twelve months to the most recent quarter.
Kwality Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 254 | 321 |
| Borrowings | 19 | 26 | 29 | 35 | 41 | 54 | 90 | 98 | 112 | 130 |
| Other liabilities | 26 | 40 | 39 | 52 | 64 | 105 | 70 | 72 | 71 | 130 |
| Total liabilities | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
| Fixed assets | 17 | 20 | 29 | 43 | 57 | 92 | 120 | 139 | 146 | 156 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 17 |
| Investments | 4 | 5 | 5 | 4 | 5 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 50 | 70 | 71 | 86 | 102 | 237 | 226 | 255 | 302 | 420 |
| Total assets | 71 | 96 | 105 | 133 | 166 | 341 | 361 | 394 | 447 | 592 |
As reported by the company. Total assets equal total liabilities by construction.
Kwality Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 | 17 |
| Cash from investing | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 | -35 |
| Cash from financing | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 | 7 |
| Net cash flow | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 | 10 | -11 |
| Free cash flow | -2 | -7 | 2 | -12 | 3 | 5 | -4 | 17 | 28 | -29 |
| CFO / operating profit | 76% | 21% | 108% | 62% | 115% | 59% | 78% | 67% | 85% | 32% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Kwality Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 19% | 22% | 18% | 26% | 98% | 19% | 16% | 18% | 24% |
| Debtor days | 84 | 98 | 84 | 79 | 50 | 55 | 104 | 136 | 152 | 203 |
| Inventory days | 71 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 | 111 |
| Days payable | 65 | 80 | 52 | 96 | 58 | 63 | 117 | 106 | 112 | 144 |
| Cash conversion cycle | 90 | 73 | 67 | 77 | 30 | 90 | 297 | 217 | 208 | 170 |
| Working capital days | 20 | 18 | 20 | 43 | 24 | 60 | 118 | 101 | 98 | 128 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Kwality Pharmaceuticals Ltd shareholding pattern
Promoters held 54.86% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.13% and DIIs 0.56%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.82% | 54.87% | 54.86% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.50% | 2.79% | 3.13% |
| DIIs | 0.02% | 0.03% | 0.32% | 0.33% | 0.33% | 0.33% | 0.36% | 0.56% |
| Public | 45.15% | 45.14% | 44.86% | 44.86% | 44.83% | 44.33% | 41.99% | 41.45% |
| No. of shareholders | 7,487 | 8,947 | 9,420 | 10,115 | 11,595 | 10,709 | 10,555 | 13,279 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kwality Pharmaceuticals Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-09-2026Company Updatelow impact
- Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Kwality Pharmaceuticals Limited Announces Board Appointments and Re-appointments Following 43rd AGMCompany Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has formalized the appointment of Mr. Swanith Kapoor as a…
Read the full analysis - Kwality Pharmaceuticals Limited Announces Successful Conclusion of 43rd Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has successfully concluded its 43rd Annual General…
Read the full analysis - Kwality Pharmaceuticals Limited Concludes 43rd Annual General Meeting; Re-appoints Key Management PersonnelAGM/EGMlow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has successfully concluded its 43rd Annual General…
Read the full analysis - Kwality Pharmaceuticals Reports Strong Q1 FY27 Financials with 127% YoY Net Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has reported robust financial results for the quarter…
Read the full analysis - Kwality Pharmaceuticals Ltd announces 43rd Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals has published a newspaper notice regarding its 43rd Annual…
Read the full analysis - Kwality Pharmaceuticals Ltd: Outcome of Investor/Analyst Meeting held on August 10, 2026Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals held an investor and analyst meeting on August 10, 2026. The…
Read the full analysis - Kwality Pharmaceuticals Q1 FY27 Earnings Call: Management Guides for INR700 Crore+ Revenue in FY27 and Outlines Ambitious Growth Path to INR1,500 Crore by FY30Company Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited management, led by CFO Aditya Arora, reaffirmed strong…
Read the full analysis - Kwality Pharmaceuticals Ltd. Raises FY27 Guidance Following Strong Q1 Performance and Strategic ExpansionCompany Updatehigh impact
Cruxal's analysis: Kwality Pharmaceuticals Ltd. has upwardly revised its FY27 revenue guidance to over 700…
Read the full analysis - Kwality Pharmaceuticals reports strong Q1 FY27 growth with 46% YoY revenue surge and raised annual guidanceBoard Meetinghigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited delivered a robust performance for the quarter ended June…
Read the full analysis - Kwality Pharmaceuticals Reports Strong FY26 Performance with 36% Revenue Growth and Raised FY27 GuidanceAGM/EGMhigh impact
Cruxal's analysis: Kwality Pharmaceuticals Limited reported a strong FY26, with consolidated revenue from…
Read the full analysis - Kwality Pharmaceuticals Ltd schedules 43rd Annual General Meeting for August 31, 2026Otherslow impact
Cruxal's analysis: Kwality Pharmaceuticals has released its Annual Report for the financial year 2025-26 and…
Read the full analysis - Kwality Pharmaceuticals Ltd announces book closure for AGMCompany Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Ltd has issued an intimation regarding the closure of its…
Read the full analysis - Kwality Pharmaceuticals Limited schedules 43rd Annual General Meeting for August 31, 2026Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has formally intimated the BSE regarding the scheduling…
Read the full analysis - Kwality Pharmaceuticals Limited Announces Board Meeting Outcome Regarding 43rd AGM and Key Management Re-appointmentsOtherslow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has announced the scheduling of its 43rd Annual General…
Read the full analysis - Kwality Pharmaceuticals to Host Q1 FY27 Earnings Conference Call on August 10, 2026Company Updatelow impact
Cruxal's analysis: Kwality Pharmaceuticals Limited has announced an Earnings Conference Call for Q1 FY…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.